Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA

被引：55
作者：
Werth, B. J. [1 ]
Vidaillac, C. [1 ]
Murray, K. P. [1 ]
Newton, K. L. [1 ]
Sakoulas, G. [3 ]
Nonejuie, P. [4 ]
Pogliano, J. [4 ]
Rybak, M. J. [1 ,2 ]
机构：
[1] Wayne State Univ, Antiinfect Res Lab, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48202 USA
[2] Wayne State Univ, Sch Med, Detroit, MI USA
[3] Univ Calif San Diego, Sch Med, Dept Pediat Pharmacol & Drug Discovery, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2013年 / 57卷 / 05期
关键词：
BETA-LACTAMS; DAPTOMYCIN; SUSCEPTIBILITY; BINDING;
D O I：
10.1128/AAC.02354-12
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates. Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively. Beta-lactam exposure reduced overall vancomycin-Bodipy (dipyrromethene boron difluoride [4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene] fluorescent dye) binding but may have improved vancomycin-cell wall interactions to improve vancomycin activity. Further research is warranted to elucidate the mechanism behind vancomycin and beta-lactam synergy.
引用
收藏
页码：2376 / 2379
页数：4
相关论文
共 24 条
[1]  
American Society for Microbiology, 2013, INSTR AUTH
[2]  
[Anonymous], 2009, M100S19 CLIN LAB STA
[3]   The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus [J].
Appelbaum, PC .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 :16-23
[4]   Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin [J].
Aritaka, N ;
Hanaki, H ;
Cui, LZ ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1292-1294
[5]   Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin [J].
Climo, MW ;
Patron, RL ;
Archer, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1747-1753
[6]   Use of Antistaphylococcal β-Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding [J].
Dhand, Abhay ;
Bayer, Arnold S. ;
Pogliano, Joseph ;
Yang, Soo-Jin ;
Bolaris, Michael ;
Nizet, Victor ;
Wang, Guiquing ;
Sakoulas, George .
CLINICAL INFECTIOUS DISEASES, 2011, 53 (02) :158-163
[7]   False synergy between vancomycin and β-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods [J].
Goldstein, FW ;
Atoui, R ;
Ben Ali, A ;
Nguyen, JC ;
Ly, A ;
Kitzis, MD .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (04) :342-345
[8]   In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus [J].
Hagihara, Mao ;
Wiskirchen, Dora E. ;
Kuti, Joseph L. ;
Nicolau, David P. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) :202-207
[9]   Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications [J].
Howden, Benjamin P. ;
Davies, John K. ;
Johnson, Paul D. R. ;
Stinear, Timothy P. ;
Grayson, M. Lindsay .
CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (01) :99-+
[10]   Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure [J].
Kelley, Peter G. ;
Gao, Wei ;
Ward, Peter B. ;
Howden, Benjamin P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) :1057-1060
123